Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
900000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)
Who receives how much900,000Shares
Shares delivered during the month: 900,000 new shares (transferred treasury shares: none stated)
EVO FUND (the allottee at the time of issuance on 8 August 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
900,000 shares delivered during the month, and an exercise ratio subject to exercise restrictions of 2.0%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price during the target month: ¥70–¥80. Details and floor of the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total issued: 110,000 rights; exercised during the target month: 9,000 rights; unexercised as of the end of the preceding month: 102,600 rights; unexercised as of the end of the target month: 93,600 rights
Procedures under the Corporate Code of Conduct
Compliance with the exercise restrictions under Article 434 of the Listing Regulations. Shares delivered across all series: 900,000 shares; listed shares as of the payment date for the issuance: 44,613,940 shares; exercise ratio subject to exercise restrictions: 2.0%
Most recent equity financing
Timing 8 August 2025 / Type 18th through 20th Stock Acquisition Rights, including the 19th Stock Acquisition Rights (with an exercise price adjustment clause) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | 19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 900,000 new shares (transferred treasury shares: none stated) |
| Intended allottee | EVO FUND (the allottee at the time of issuance on 8 August 2025) |
| Dilution Rate | 900,000 shares delivered during the month, and an exercise ratio subject to exercise restrictions of 2.0% |
| Total number of issued shares | As of the end of the month preceding the target month: 55,072,640 shares → Not disclosed |
| Exercise price | Exercise price during the target month: ¥70–¥80. Details and floor of the adjustment clause: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 110,000 rights; exercised during the target month: 9,000 rights; unexercised as of the end of the preceding month: 102,600 rights; unexercised as of the end of the target month: 93,600 rights |
| Procedures under the Corporate Code of Conduct | Compliance with the exercise restrictions under Article 434 of the Listing Regulations. Shares delivered across all series: 900,000 shares; listed shares as of the payment date for the issuance: 44,613,940 shares; exercise ratio subject to exercise restrictions: 2.0% |
| Most recent equity financing | Timing 8 August 2025 / Type 18th through 20th Stock Acquisition Rights, including the 19th Stock Acquisition Rights (with an exercise price adjustment clause) / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status in May 2026 of the 19th Stock Acquisition Rights issued on 8 August 2025.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.